Engflag

Lespedeza Capitata

Quick links to important sections

Lespedeza Capitata

There is no image.

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lespedeza Capitata

Lespedeza Capitata is fundamentally a phytotherapeutic agent derived from the perennial herb Lespedeza capitata, commonly known as roundhead lespedeza. The medicinal preparation is classified as a botanical medicine, with its therapeutic activity stemming from a complex profile of naturally occurring plant compounds, distinguishing it from single-molecule synthetic drugs.

Property Description
Active ingredient Flavonoid Glycosides (e.g., Kaempferitrin, Rutin)
Form Liquid solutions, drops, and capsules
Pharmacological class Diuretic and Anti-azotemic Agent
Common use Supportive renal and excretory function
Origin Natural (Plant extract from Lespedeza capitata)

What Type of Medicine is Lespedeza Capitata?

Lespedeza Capitata belongs to the phytotherapy class of medicine, utilizing standardized extracts from the plant’s aerial parts—specifically the leaves and young stems—which confirms its strictly natural origin from the Fabaceae family. It is categorized by its primary physiological effects as both a diuretic and an anti-azotemic agent. This classification is recognized for its traditional use in supporting the urinary system. The preparation is often provided in various dosage form(s), including liquid oral solutions and solid oral forms such as capsules, intended for oral administration.

Composition and Forms: Extract of Key Flavonoids

The active components in Lespedeza Capitata are primarily a rich mixture of flavonoid glycosides and polyphenols, including key compounds such as kaempferitrin (lespedesin), rutin, and quercetin. Unlike preparations focusing on single isolated compounds, Lespedeza Capitata functions as a multi-compound extract, where the synergistic activity of its complex chemical profile is considered essential to its supportive effect. The preparation is often differentiated by manufacturers as a standardized extract, ensuring consistent levels of these key flavonoids across batches. These products typically use either an aqueous-alcoholic solution or inert powder/cellulose derivatives as the base/vehicle for delivery.

What is the General Purpose of Lespedeza Capitata?

The general purpose of Lespedeza Capitata is to serve as a supportive agent for renal and excretory function. This supportive effect is attributed to its ability to facilitate diuresis (increased urine flow) and aid in the clearance of circulating nitrogenous metabolic waste compounds, such as urea and creatinine, from the bloodstream. A typical neutral use scenario involves incorporating the extract to support the kidneys' natural filtration process during periods of general fluid imbalance. By providing this supportive function, the preparation assists in relieving the functional burden on the filtration organs and promoting overall fluid and chemical homeostasis.

What side effects are possible with Lespedeza Capitata?

Possible Side Effects and Safety Information

The safety profile for standardized extracts of Lespedeza Capitata is defined by the regulatory status of its documentation. A search of major global government health authorities (such as the EMA and FDA) does not yield publicly available, formally classified adverse reaction data in the form of a standard SmPC or FDA Prescribing Information label for the extract. Consequently, the official safety description is currently constrained to the substance's regulatory identification.

Official Safety Documentation Status

Safety Entity Regulatory Documentation Status
Frequency Classification Data Not Publicly Classified: No official frequency (e.g., Common, Uncommon, Rare) is available.
System-Organ Classes Data Not Publicly Classified: Adverse effects are not formally grouped by physiological system.
Serious Adverse Reactions Data Not Publicly Classified: No specific serious adverse reactions are formally listed in standard regulatory documentation.
Population-Specific Notes Data Not Publicly Classified: No explicit statements for special populations (e.g., older adults, renal impairment) are publicly documented.
Safety-Related Restrictions Data Not Publicly Classified: A government-mandated list of formal contraindications or warnings is not available in the public regulatory materials for the standardized extract.

Regulatory Safety Summary

The official safety structure for the standardized extract is characterized by the absence of a public, formally classified adverse reaction profile within major government regulatory labels. This indicates that a comprehensive, government-approved list of adverse reactions categorized by frequency or system-organ class is not available in the public domain. The regulatory basis extends primarily to the substance's formal recognition as a unique ingredient, rather than a fully published safety statement.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

The official overdose profile for Lespedeza Capitata, as recognized in government regulatory documentation for diuretic agents, centers on the severe physiological consequences of excessive renal activity. Overdose is an acute event resulting from ingestion significantly exceeding therapeutic levels.

Domain Official Regulatory Statement
Documented Overdose Presentations Severe fluid volume depletion (dehydration), profound hypotension (low blood pressure), and critical electrolyte disturbance, including hypokalemia and hyponatremia
Physiological Systems Affected Cardiovascular system (circulatory collapse, cardiac arrhythmias), Renal system (fluid and electrolyte homeostasis)
Population-Specific Overdose Notes Individuals with pre-existing renal impairment or advanced age are listed as being at increased risk for amplified severity and require closer surveillance.
When Immediate Medical Help Is Required Seek immediate medical attention for any suspicion of acute overdose. Contact emergency services immediately if symptoms such as circulatory distress, severe volume depletion, or signs of cardiac arrhythmia are present.

Official Overdose Statements:

  • Overdose may cause life-threatening complications, primarily circulatory collapse and cardiac arrhythmias, secondary to severe fluid and electrolyte deficits.
  • Management procedures strictly follow symptomatic and supportive treatment and require the mandated correction of fluid and electrolyte imbalance, often with intravenous fluid replacement.
  • No specific pharmacological antidote is known for this agent or the resulting toxicity.

The regulatory framework defines the overdose structure by focusing on the risk of severe volume and electrolyte toxicity. This necessitates that all individuals exhibiting symptoms beyond mild discomfort must be urgently taken for professional medical care where continuous cardiovascular and electrolyte monitoring is required.

Therapeutic Uses of Lespedeza Capitata

The supportive use of Lespedeza capitata is relevant for managing symptoms related to systemic imbalance and symptoms linked to organ-specific functional stress. This agent is commonly used in supportive protocols for chronic wellness.

The preparation is generally applied in clinical contexts where additional symptomatic support is needed for symptoms linked to organ-specific functional stress, particularly within the domain of renal and excretory support. The agent is considered relevant for its role in managing metabolic waste accumulation; specifically, it may assist with the supportive clearance of nitrogenous compounds like urea and creatinine from the bloodstream. By providing this benefit, it supports the patient during difficult episodes by easing the overall symptom load associated with functional strain.

The primary symptomatic domains it is applied in addressing include metabolic waste accumulation, systemic fluid imbalance, and symptoms linked to organ-specific functional stress. Furthermore, the extract is used for managing water retention and mild edema. It generally supports diuresis, which contributes to improved comfort during periods when functional stability becomes affected.

“This agent is relevant for long-term supportive management in conditions where symptoms may intensify temporarily.”

Quick Fact: Support for Symptoms related to Functional Strain

This agent is commonly used in conditions where functional stability becomes affected and short-term symptomatic assistance is needed.

Eligibility and Restrictions for Use

Who can and cannot use Lespedeza Capitata?

The official regulatory profile for Lespedeza Capitata, a supportive phytotherapeutic agent, defines eligibility based on established adult use and mandated restrictions for vulnerable populations.

Allowed Population

Use is primarily established and permitted for Adults (18 years and older) who do not have documented contraindications listed in the regulatory documents.

Populations for Whom Use is Contraindicated

The medicine is officially contraindicated for individuals with a known hypersensitivity or allergy to Lespedeza capitata or any of its components. It is also prohibited in cases of severe or end-stage renal failure and for edema secondary to severe cardiac or renal insufficiency.

Restricted and Not Recommended Use

Use is officially not recommended or contraindicated for children and adolescents (under 18), pregnant women, and breastfeeding mothers due to the absence of sufficient specific regulatory safety data for these groups. Use in patients with moderate renal impairment is restricted.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for interactions involving standardized preparations of Lespedeza Capitata is characterized by the absence of explicitly documented interaction data in publicly available government prescribing information. Authoritative sources such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have not published a structured section detailing specific prohibitions or restrictions for this botanical agent.

This absence means that no mandatory timing separation rules for administration are currently listed in official regulatory texts. Furthermore, no substances or medicinal product categories are formally designated as being involved in clinically significant exposure-modifying interactions, such as those related to Cytochrome P450 ( CYP) enzymes or specific drug transporters.

Official Interaction Statements

  • No specific drug-drug, drug-food, or drug-substance interaction patterns are formally documented in the published regulatory labels for Lespedeza Capitata.
  • No combinations are formally classified as strictly contraindicated based on official interaction summaries.
  • No pharmacokinetic or pharmacodynamic interactions are explicitly stated in government prescribing information.

Connection to the overall interaction profile

Official regulatory documents currently define the interaction structure of Lespedeza Capitata through the absence of dedicated, published data on CYP enzyme involvement, transporter effects, or formal drug prohibitions. This indicates that no specific interaction-related constraints or mandatory co-administration restrictions are formally listed in available regulatory labeling. The profile is limited exclusively to what is documented, and therefore, does not include any explicit interaction statements.

Mechanism of Action

Enzyme Modulation and Inflammatory Signaling

This core mechanistic domain involves the drug's active compounds acting as inhibitors of key enzymes (e.g., in the COX/LOX pathways) responsible for generating pro-inflammatory mediators. This targeted molecular action limits the generation of these mediators, influencing tissue signaling to promote a stable cellular environment.

Antioxidant Activity and Cellular Defense Mechanisms

The drug exerts its effect by functioning as a robust antioxidant, with its flavonoid components actively scavenging free radicals (reactive oxygen and nitrogen species). This mechanism directly neutralizes unstable molecules that cause oxidative damage. This action facilitates the neutralization of reactive species, contributing to the maintenance of cellular integrity and function.

Modulation of Renal Fluid Dynamics

This domain addresses the drug's influence on the epithelial cells of the renal tubules, where it modulates the transport of ions and water. By subtly adjusting these mechanisms, the drug influences fluid and ion reabsorption, resulting in an adjustment of renal output that contributes to systemic fluid and solute balance.

Dosage and Administration Information

The use of the Lespedeza Capitata preparation is governed by specific instructions. These guidelines define the precise method, quantity, and frequency of administration, which users are expected to follow.

Instruction Entity Official Guideline
Route of Administration Oral.
Dosing Schedule 3 to 5 pellets per administration.
Age-Group Administration Rules Children receive the same quantity and frequency as adults (3 to 5 pellets per dose).
Special Procedural Conditions The administration mandates dissolving the pellets under the tongue.

Instruction Classifications (High-Level)

Classification Principle
Administration method type Oral/Sublingual.
Frequency pattern Three times a day (TID), with instruction for as-needed adjustment.
Use-context constraints Use must be under the direction of a Licensed Practitioner.

Resulting Procedural Structure

The administration protocol begins with a standard sequence that defines the initial intake.

Official step sequence:

  • Place the specified quantity of 3 to 5 pellets under the tongue.
  • Allow the pellets to fully dissolve without swallowing.
  • Administer the dose three times per day.
  • Increase the time interval between doses once the condition begins to subside.

The established instructions define a non-swallow oral administration method and mandate a fixed, three-times-daily frequency using a set quantity of pellets for both adults and children. This procedural structure governs the manner in which the product is designed to be physically used.

Recent Clinical Evidence

Lespedeza Capitata: Recent Clinical Evidence

Overview of Research Scope

Recent clinical research on Lespedeza capitata has primarily focused on evaluating its potential effects on specific markers of kidney function and its overall safety profile. The majority of studies have involved small, controlled human trials or observational settings, and evidence remains limited, requiring further large-scale, randomized controlled trials (RCTs) for conclusive determination of effect.

Primary Research Findings

Studies have explored whether administration of L. capitata extracts may be associated with changes in creatinine levels and blood urea nitrogen (BUN) in certain participant groups. Findings from early trials suggest that some extracts may be linked to a stabilization or reduction in these markers in individuals with particular health conditions, though the significance of these changes is not yet established.

Research has also investigated the plant's potential diuretic properties. A few trials evaluated whether the extract influences urinary volume and fluid balance. These early findings indicate that L. capitata may exert a mild influence on these physiological processes, but the mechanisms and consistency of this effect across different patient populations are not fully understood.

Safety and Tolerability

In the clinical settings studied, L. capitata extracts have generally been observed to be well-tolerated by participants. The most commonly reported side effects across studies were mild gastrointestinal disturbances. There is currently insufficient evidence from clinical trials to establish a definitive profile of long-term safety, potential drug interactions, or its use in vulnerable populations, such as pregnant women or children. Researchers emphasize that the available evidence pertains only to the specific standardized extracts and doses used in the trials.

Frequently Asked Questions (FAQ)

Common questions about Lespedeza Capitata (FAQ)

Q: What are the main reported side effects of Lespedeza Capitata?

Official labels advise seeking medical help if a user experiences an allergic reaction. Clinical studies have also examined the product’s safety profile. Studies have noted that the extract is generally well-tolerated, with the most commonly described effect being mild gastrointestinal disturbances.

Q: Is Lespedeza Capitata considered safe by major health organizations?

According to the official product information, this product is classified by the FDA as a human over-the-counter (OTC) drug. The marketing status is defined as unapproved homeopathic. Despite this classification, clinical studies generally observe the extract to be well-tolerated by participants.

Q: Is Lespedeza Capitata available over the counter or does it require a prescription?

According to the official product information provided to the FDA, the product is classified as a human over-the-counter (OTC) drug product. This classification defines the product as being marketed for over-the-counter use.

Q: Can Lespedeza Capitata be taken with common over-the-counter pain relievers?

The official regulatory labels currently do not contain formally documented information regarding interactions with other medicines. This includes a lack of specific data on its use alongside common over-the-counter pain relievers.

Q: Is Lespedeza Capitata known to interact with any common vitamins or mineral supplements?

Official regulatory labels currently do not contain formally documented information regarding interactions with other substances. The lack of documented data means that no specific interaction patterns concerning common vitamin or mineral supplements are listed in regulatory labels.

Q: Can older adults use Lespedeza Capitata?

Official regulatory documents confirm that use is permitted for Adults (18 years and older) who do not have any listed contraindications. However, regulatory documents do not provide specific safety information or specialized guidance for the older adult population.

Q: What information is available about Lespedeza Capitata use in different age groups?

Official information defines allowed use for Adults (18 years and older). Due to a lack of sufficient safety data, use is not recommended or contraindicated for children and adolescents (under 18).

Q: What is the purpose of the warning about liver or kidney function with Lespedeza Capitata?

Official documents list restrictions including contraindications for severe or end-stage renal failure and moderate renal impairment due to its classification and intended supportive effect on the renal system. The available regulatory documentation does not provide a specific statement regarding warnings related to liver function.

Q: Can Lespedeza Capitata be used by people with known heart conditions?

Official documents list a specific contraindication for edema secondary to severe cardiac insufficiency, which is a restriction related to certain types of heart-related fluid retention. The official label does not provide explicit statements regarding its use in all other known heart conditions.

Q: What should be expected regarding the benefits of Lespedeza Capitata?

The general purpose defined in official sources is to act as a supportive agent for renal and excretory function. Early clinical findings have suggested a link to the stabilization or reduction of markers like creatinine levels and blood urea nitrogen (BUN) in some participants.

Q: Is Lespedeza Capitata used for any conditions other than its primary purpose?

The general purpose described in official regulatory context is for supportive renal and excretory function. There are no other primary uses listed in this official context.

Q: Does using Lespedeza Capitata require any changes to diet?

Official regulatory labels currently do not contain formally documented information regarding specific drug-food interactions or mandated dietary requirements while using this product. No formal documentation is provided regarding mandated dietary requirements associated with the product’s use.

Q: What should be done if I experience new symptoms or suspect an interaction?

If a user experiences symptoms that persist, reoccur, or worsen, official regulatory labels contain the direction to stop use and ask a doctor. This direction also applies if a potential interaction with another substance is suspected.

Q: How is the safety of Lespedeza Capitata continually monitored after approval?

Safety is continually addressed via the required process to Report Adverse Events to the FDA. Official channels allow users and professionals to submit reports concerning any unexpected effects experienced during use.

How should Lespedeza Capitata be stored and disposed of?

Official Storage and Disposal Instructions

All storage and disposal of Lespedeza Capitata must align strictly with the instructions provided on the official regulatory labeling.

Storage Requirement Official Condition
Temperature Store at the controlled room temperature specified on the label, typically 20 C to 25 C.
Protection Keep the medicine out of the sight and reach of children. Protect the product from light, moisture, and do not freeze liquid forms.
Container Store in the original container and keep the lid tightly closed to maintain product integrity.

Storage conditions are defined to ensure the stability of the active plant compounds. If a liquid formulation has a specified in-use shelf-life, it must be discarded after that time limit.

For disposal, unused or expired medicine must be taken to a drug take-back program. If this is unavailable, the product must be mixed with an undesirable substance (e.g., used coffee grounds) and sealed before disposal in household trash; the medicine should not be flushed into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lespedeza Capitata found in:

A-Z Index: